Juan Graham Acquires 33,333 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CFO Juan Graham bought 33,333 shares of the business’s stock in a transaction on Friday, March 28th. The stock was purchased at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the purchase, the chief financial officer now directly owns 35,354 shares in the company, valued at approximately $79,546.50. This represents a 1,649.33 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Perspective Therapeutics Trading Up 4.6 %

NYSE:CATX opened at $2.05 on Thursday. The firm’s fifty day moving average price is $2.85 and its two-hundred day moving average price is $6.07. Perspective Therapeutics, Inc. has a one year low of $1.90 and a one year high of $19.05.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC boosted its holdings in shares of Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after acquiring an additional 5,370,392 shares during the period. Janus Henderson Group PLC lifted its holdings in Perspective Therapeutics by 8.0% during the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after purchasing an additional 355,685 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its stake in Perspective Therapeutics by 4.3% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock valued at $9,375,000 after purchasing an additional 120,991 shares during the period. Octagon Capital Advisors LP grew its holdings in Perspective Therapeutics by 62.1% in the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock valued at $7,352,000 after buying an additional 882,528 shares in the last quarter. Finally, State Street Corp increased its position in Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after buying an additional 1,192,812 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on CATX. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a report on Monday. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Finally, Scotiabank assumed coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $14.44.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.